Welcome to WordPress. This is your first post. Edit or delete it, then start blogging!
Management and strategy consulting for life science companies
Welcome to WordPress. This is your first post. Edit or delete it, then start blogging!
6/27/2012 – “High Points and Hurdles: Immunotherapy Moves Forward” by Anita T. Shaffer of OncLive
5/7/2012 – “Insight: Training immune system to fight cancer comes of age” by Bill Berkrot of Reuters
3/2/2012 – “Biotech Stock Mailbag: Cyclacel Fallout, the Skinny on Vivus, Celldex’s Crash” by Adam Feuerstein of TheStreet.com
2/27/2012 – “Dendreon Shares Drop on Slowing Sales of Cancer Vaccine Provenge” by Brett Chase of Minyanville
1/26/2012 – “Amgen, Celgene, Roche Deals Signal M&A Frenzy for Drug Companies” by Brett Chase of Minyanville
1/5/2012 – “Dendreon reports spike in Provenge sales; shares soar” by Bill Berkrot of Reuters
10/11/2011 – “Nobel prize-winning science should incubate deals” by David Holley of The Deal
10/7/2011 – “Zytiga creeps up on Provenge prostate-cancer drug” by Ransdell Pierson of Reuters
8/23/2011 – “What’s a Cancer Drug Worth?” by Brett Chase of Minyanville
Legal Disclaimer | © 2013MD Becker Partners LLC • Built on the Genesis Framework